Today we examine whether the demand for PrEP has already been satisfied.
This short interview highlights the importance of trans women in HIV research.
Today's PrEP myth examined: that it's only accessible to the affluent.
Today we look at the question of whether taking Truvada for PrEP will create a resistant HIV strain.
Today we look at the assertion that PrEP won't really make a dent in the number of new HIV infections.
Today we look at the idea that PrEP is a marker of promiscuity.
If you think there's no difference, you may want to give it more thought.